Jazz Venture Partners

JAZZ Venture Partners Research Investment Thesis JAZZ Venture Partners invests in transformative technologies that unlock human potential at the convergence of technology, science, and humanity. Founded in 2015 and headquartered in San Francisco with offices in Seattle and Santa Barbara, the firm believes that breakthroughs in science and technology can vastly improve how we live, work, and experience the world. The firm's mission is to partner with founders creating companies that measurably improve human health, performance, productivity, and wellbeing. Core Focus Areas JAZZ focuses on three primary investment domains: Health & Wellness: Digital therapeutics, mental health, neuroscience, biotech, medical devices, and healthcare innovations that improve human health outcomes. Productivity & Enterprise: Technologies that augment human performance in the workplace, including AI-driven productivity tools, robotics, automation, and enterprise software. Consumer & Lifestyle: Consumer applications and platforms that enhance how people live, work, and experience the world, including fitness, wellness, meditation, and lifestyle technologies. Stage Focus JAZZ primarily invests at Seed through Series B, with a strong focus on early-stage companies: Pre-Seed: Selective investments in exceptional teams Seed: Core investment stage Series A: Primary deployment stage Series B: Follow-on investments and select new opportunities The firm has made investments across all these stages, demonstrating flexibility while maintaining focus on early-stage companies with transformative potential. Check Size Investment sweet spot: $1.5 million Investment range: $100,000 - $150,000,000 Typical check sizes: $500,000 - $5,000,000 The wide range reflects the firm's ability to participate in larger rounds alongside other investors, but their core focus is on meaningful seed and Series A investments that support early-stage growth. Lead Tendency JAZZ demonstrates both lead and follow-on investment patterns. The firm frequently leads rounds (particularly at Seed and Series A) but also participates in larger Series B and beyond investments within their portfolio. Recent activity shows participation in Series A and B rounds with other institutional investors. Investment Philosophy The firm explicitly states: "JAZZ seeks breakthroughs at the convergence of technology, science, and humanity — improving how we live, work, and experience the world." This reflects a deeply held belief that the best investments come from addressing fundamental human needs and challenges with scientific rigor and technological innovation. Key philosophical principles: Founder-Centric: Partners closely with founders and management teams, providing mentorship and industry connections Hands-On Support: Team members serve on boards of portfolio companies to guide strategy and growth Interdisciplinary Expertise: Leverages deep expertise in engineering, neurology, cognitive science, AI, design, and life sciences Long-Term Impact: Focuses on companies creating sustained positive impact, not just financial returns Team Expertise The firm assembles partners with exceptional credentials: Andrew Firlik (Managing Partner): Neurosurgeon, former partner at Flare Capital and Canaan Partners. Founded Northstar Neuroscience (IPO, acquired by St. Jude). Published 50+ medical articles, served as clinical professor at Yale and NYU. John F. Harris (Managing Partner): 30+ years building and directing life sciences and technology companies. Founded NeuroVista (epilepsy management) and Northstar Neuroscience. Founded Heartstream (acquired by HP), which revolutionized cardiac defibrillation. Zack Lynch (Managing Partner): Venture capitalist and entrepreneur with deep expertise in neurotechnology and wellness. Founded multiple consumer wellness companies. Author of "The Neuro Revolution." Track record from seed funding through IPO. John Spinale (Managing Partner): Consumer technology and digital media expert. 20+ years building and scaling high-growth companies from seed through late-stage operations. Deep understanding of brand building and emerging platforms. John Lee (Partner): Focused on frontier technology, enterprise software, robotics, healthcare, and AI. Previously at Lux Capital and Osage University Partners. Expertise in deep technology commercialization and product translation. Justin Nuñez (Partner): Leads Capital Formation & Investor Relations. Nearly a decade at TPG ($150B global alternative investment firm). Co-founded TPG NEXT, focusing on diverse entrepreneurs and investors. Additional strength through Venture Partners including: Sharon Knight (health tech operations), Chris Flink (product design and user experience), Jia Li (AI and generative AI applications), Chit-Kwan Lin (machine learning and hardware), Ido Leffler (consumer brands), Adam Gazzaley (neuroscience), and Matt Wan (health and human performance). Recent Activity & Portfolio Quality As of late 2024/early 2025, JAZZ has invested in 58-64 companies with notable momentum: Recent notable investments (2025): Bonito Biosciences (October 2025) - AI and mRNA display for drug discovery Justpoint (February 2025) - AI platform identifying harmful substances Recent portfolio highlights: Akili Interactive (IPO) - Scientifically validated video games for mental health Pear Therapeutics (IPO) - Prescription digital therapeutics pioneer Colossal Biosciences - CRISPR and biodiversity ($150M Series B) Cadence Neuroscience - Brain-computer interfaces ($41M total invested) Embodied - Robotics and AI companion robots (acquired) Oura - Sleep and activity optimization wearables (IPO potential) Insight Timer - Meditation marketplace, 25M+ members JobGet - Mobile jobs platform for hourly workers Outside - Active lifestyle technology and media Woebot - AI-driven mental health care Thrive Global - Peak performance and behavior change The firm has generated multiple exits including acquisitions (Embodied, AllStripes, Blue Note, HerMD, Oma, and others) and IPOs (Akili, Pear Therapeutics). This demonstrates strong exit outcomes and return generation. Fund Status The firm manages approximately $287 million in assets under management from its most recent fund. They are actively deploying capital, with investments recorded through late 2025. The firm appears to be in active fundraising or between funds based on the timing of their raises and deployment. Decision Process JAZZ operates as a partnership with multiple Managing Partners who bring diverse expertise. Investment decisions appear to reflect partnership consensus with individual partners taking board seats based on expertise. The firm's emphasis on hands-on involvement suggests a collaborative, partnership-oriented approach to investment decisions rather than a committee-based structure. Geographic Focus Primary: United States (particularly SF Bay Area, Seattle, California) Secondary: Selective international investments (Canada, Israel, Europe) Headquarters: San Francisco, CA Additional offices: Seattle, WA and Santa Barbara, CA Warm Introduction Requirements Given the firm's relationship-oriented approach and partnership structure, warm introductions are valued. The firm actively participates in the founder community and maintains extensive co-investor networks. Notable Co-Investors Frequent co-investors include: The General Partnership (Phin Barnes) Union Square Ventures (Albert Wenger) New Enterprise Associates (NEA) Lux Capital (Josh Wolfe) Bee Partners American Express Ventures Market Position JAZZ occupies a unique position in venture capital: Specialized Focus: Deeply focused on human performance and wellbeing, not generalist Scientific Credibility: Partners with medical and scientific backgrounds provide unique domain expertise Hands-On Governance: High level of board participation and operational involvement Proven Exits: Strong track record with multiple IPOs and strategic acquisitions Interdisciplinary Network: Access to scientists, entrepreneurs, and technologists across multiple domains The firm is comparable to but distinct from other health/biotech/wellness-focused VCs due to its emphasis on both high-tech innovation and human science integration. Investment Criteria Companies that fit JAZZ's investment thesis typically: Address fundamental human challenges with science and technology Have exceptional founding teams with complementary expertise Operate at the intersection of multiple disciplines (technology + science + humanity) Show potential for significant impact beyond financial returns Operate in health, productivity, wellness, or consumer sectors Demonstrate path to scalability and sustainable business models Performance Metrics The firm's portfolio includes multiple IPOs, unicorn candidates, and strategic acquisitions, demonstrating strong return generation. The breadth of exits (both IPOs and acquisitions) and the quality of portfolio companies (many with significant revenue and user bases) indicate effective investment selection and portfolio company support.